Effectiveness of Doxepin for Insomnia
Efficacy Profile
- Low-dose doxepin (3 mg and 6 mg) demonstrates clinically significant improvements in sleep maintenance parameters, including wake after sleep onset (WASO), total sleep time (TST), and sleep efficiency (SE), with minimal adverse effects, as recommended by the American Academy of Sleep Medicine 1, 2
- The American Academy of Sleep Medicine suggests that low-dose doxepin improves WASO, TST, and SE at both 3 mg and 6 mg doses, with moderate improvement in sleep quality at 3 mg and mild improvement at 6 mg 1, 3
Safety Profile
- Low-dose doxepin (3 mg and 6 mg) has a safety profile comparable to placebo in clinical trials, with only a mild increase in somnolence at the 6 mg dose, as reported by the American Academy of Sleep Medicine 1, 3
- The American Academy of Sleep Medicine and the VA/DoD guidelines recognize that low-dose doxepin may have higher adverse event rates with longer treatment duration 2, 5
Clinical Guidelines Recommendations
- The American Academy of Sleep Medicine suggests using doxepin as a treatment for sleep maintenance insomnia (weak recommendation), and the VA/DoD guidelines recommend considering low-dose doxepin for patients unable or unwilling to receive Cognitive Behavioral Therapy for Insomnia (CBT-I) 1, 2, 4, 6
- Both guidelines emphasize that doxepin should be administered at the lowest effective dose (3 or 6 mg) and for the shortest possible duration, as recommended by the American Academy of Sleep Medicine and the VA/DoD 2, 6